|
1) Yatabe Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev. 2010: 29: 23-36
|
|
|
|
2) Giordano TJ, Shedden KA, Schwartz DR, et al. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol. 2001; 159: 1231-8
|
|
|
|
|
|
3) Shedden KA, Taylor JM, Giordano TJ, et al. Accurate molecular classification of human cancers based on gene expression using a simple classifier with a pathological tree-based framework. Am J Pathol. 2003; 163: 1985-95
|
|
|
|
|
|
4) Tothill RW, Kowalczyk A, Rischin D, et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res. 2005; 65: 4031-40
|
|
|
|
|
|
5) Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 2001; 98: 13784-9
|
|
|
|
|
|
6) Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001; 98: 13790-5
|
|
|
|
|
|
7) Borczuk AC, Gorenstein L, Walter KL, et al. Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol. 2003; 163: 1949-60
|
|
|
|
|
|
8) Tomida S, Koshikawa K, Yatabe Y, et al. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene. 2004: 23: 5360-70
|
|
|
|
|
|
9) Takeuchi T, Tomida S, Yatabe Y, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol. 2006; 24: 1679-88
|
|
|
|
|
|
10) Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002; 8: 816-24
|
|
|
|
|
|
11) Shibata T, Hanada S, Kokubu A, et al. Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma. Cancer Sci. 2007; 98: 985-91
|
|
|
|
|
12) Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008; 32: 810-27
|
|
|
|
|
|
13) Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers－a different disease. Nat Rev Cancer. 2007; 7: 778-90
|
|
|
|
|
|
14) Subramanian J, Govindan R. Lung cancer in never smokers: a review. J Clin Oncol. 2007; 25: 561-70
|
|
|
|
|
|
15) Rudin CM, Avila-Tang E, Samet JM. Lung cancer in never smokers: a call to action. Clin Cancer Res. 2009; 15: 5622-5
|
|
|
|
|
|
16) Patel JD, Bach PB, Kris MG. Lung cancer in US women: a contemporary epidemic. JAMA. 2004; 291: 1763-8
|
|
|
|
|
|
17) Yatabe Y, Kosaka T, Takahashi T, et al. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol. 2005; 29: 633-9
|
|
|
|
|
|
18) Noguchi M. Stepwise progression of pulmonary adenocarcinoma－clinical and molecular implications. Cancer Metastasis Rev. 2010; 29: 15-21
|
|
|
|
|
|
19) Yatabe Y, Takahashi T, Mitsudomi T. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res. 2008; 68: 2106-11
|
|
|
|
|
|
20) Guerra C, Mijimolle N, Dhawahir A, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell. 2003; 4: 111-20
|
|
|
|
|